Table 2.
Events in PMBCL Patients
| No. | Therapy Arm | Response at the End of Treatment |
Further Therapy | EFS Event | PFS Event | Further Therapy | Survival Status; Survival Time (mo) |
|---|---|---|---|---|---|---|---|
| 1 | R-CHOP-21 | Partial response | Radiotherapy | Partial response at the end of study therapy | No | Alive (135 mo) | |
| 2 | R-CHOP-21 | Partial response | Radiotherapy | Partial response at the end of study therapy | No | Alive (109 mo) | |
| 3 | R-CHOP-21 | CR/CRu +additional treatment | Radiotherapy | Application of additional treatment | No | Alive (120 mo) | |
| 4 | R-CHOP-21 | Progressive disease | progressive disease | Progressive disease | Autologous stem cell transplantation | Alive (113 mo) | |
| 5 | R-CHOP-21 | CR/CRu | Relapse | Relapse | Radiotherapy | Alive (94 mo) | |
| 6 | R-CHOP-21 | CR/CRu | Relapse | Relapse | Autologous stem cell transplantation +radiotherapy | Alive (87 mo) | |
| 7 | R-CHOP-21 | CR/CRu | Relapse | Relapse | Allogenic stem cell transplantation | Death (20 mo) | |
| 8 | R-CHOP-21 | Partial response | Radiotherapy | Partial response at the end of study therapy | No | Alive (81 mo) | |
| 9 | R-CHOP-14 | Partial response | Autologous stem cell transplantation +radiotherapy | Partial response at the end of study therapy | No | Alive (132 mo) | |
| 10 | R-CHOP-14 | Progressive disease | Progressive disease | Progressive disease | Burkitt protocol | Death (18 mo) | |
| 11 | R-CHOP-14 | Partial response | Radiotherapy | Partial response at the end of study therapy | No | Alive (88 mo) | |
| 12 | R-CHOP-21 + radiotherapy |
Partial response | 2x R-CHOP+radiotherapy | Partial response at the end of study therapy | Relapse | Autologous stem cell transplantation | Alive (134 mo) |
| 13 | R-CHOP-21 + radiotherapy |
Progressive disease | Progressive disease | Progressive disease | Autologous stem cell transplantation | Death (10 mo) | |
| 14 | R-CHOP-14 + radiotherapy |
Unknown | Auto SCT + rituximab consolidation | Unknown response at the end of study therapy, application of additional treatment | No | Alive (107 mo) | |
| 15 | R-CHOP-14 + radiotherapy |
Progressive disease | Progressive disease | Progressive disease | Autologous stem cell transplantation +radiotherapy, allogenic stem cell transplantation, lymphocytes | Alive (51 mo) | |
| 16 | R-CHOP-14 + radiotherapy |
Partial response | Partial response at the end of study therapy | Progressive disease | Unknown | Death (9 mo) |
CR/CRu = complete response/unconfirmed complete response; EFS =event-free survival; PFS = progression-free survival; PMBCL = primary mediastinal B-cell lymphoma; R-CHOP = rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; SCT = stem cell transplantation.